Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Phase 2 Completed 31 enrolled Novartis Pharmaceuticals Chugai Pharmaceutical · collab

NaSingle-groupOpen-labelTreatment

Summary

To investigate the safety and efficacy of letrozole monotherapy at a dose of 2.5 mg/day in postmenopausal patients with breast cancer, and to determine the blood concentrations of letrozole and hormones.

Timeline

Start: 2001-06
Primary completion: 2006-10
Completion: 2006-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Letrozole	Other / unclassified	2.5 mg	—

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Summary

Timeline

Drugs

Indications